Boston Scientific (NYSE: BSX) sets $700–$800 million restructuring with $500 million savings

Boston Scientific Corporation approved a new global restructuring program, the 2026 Restructuring Plan, on July 21, 2026. The plan is intended to drive sustained cost efficiencies and support growth by optimizing the supply chain, transferring certain production lines among facilities, and reshaping functional and organizational structures.

The program is expected to be initiated in 2026 and substantially completed by the end of 2029. Boston Scientific estimates total pre-tax charges of $700 million to $800 million, including $300 million to $350 million of transfer costs, $275 million to $300 million of termination benefits, and $125 million to $150 million of other costs such as consulting, contractual cancellations, program management, accelerated depreciation and fixed asset write-offs. Of the total charges, $600 million to $700 million are expected to result in future cash outlays.

The company expects the plan to reduce gross annual pre-tax expenses by approximately $500 million as benefits are realized, with a substantial portion of these savings to be reinvested in strategic growth initiatives. While new roles will be created in growth areas, the company does expect some headcount reductions as a result of the restructuring.

https://www.stocktitan.net/sec-filings/BSX/8-k-boston-scientific-corp-reports-material-event-7b99b8a295ca.html